Table 7 Recurrence rates of relevant treatment options reported in RCTs
Author | Year | Length of follow-up in months (number of patients at last follow up) | Number of patients (limbs) | Recurrence rate |
|---|---|---|---|---|
ClosureFast vs. Surgery vs. UGFS | ||||
Rasmussen [18] | 2011 | 12 (ClosureFast: 106 Surgery: 97 UGFS: 107) | ClosureFast: 125 (148) | ClosureFast: 9/124 = 7.26% |
Surgery: 125 (143) | Surgery: 16/108 = 14.81% | |||
UGFS: 125 (145) | UGFS: 17/123 = 13.82% | |||
Odds ratio (ClosureFastvs Surgery): 0.45 | ||||
Odds ratio (ClosureFastvs UGFS): 0.49 | ||||
Odds ratio (UGFS vs Surgery): 0.92 | ||||
ClosurePlus vs. Surgery | ||||
Perälä [36] | 2005 | 36 (ClosurePlus: 15 Surgery: 13) | ClosurePlus: 15 (15) | ClosurePlus: 5/15 = 33.33% |
Surgery: 13 (13) | Surgery: 3/13 = 23.1% | |||
Odds ratio: 1.67 | ||||
Lurie [64] | 2005 | 24 (ClosurePlus: 36 Surgery: 29) | ClosurePlus: 43 (44) | ClosurePlus: 5/36 = 13.89% |
Surgery: 36 (36) | Surgery: 6/29 = 20.69% | |||
Odds ratio: 0.62 | ||||
Helmy Elkaffes [65] | 2011 | 24 (ClosurePlus: 81 Surgery: 81) | ClosurePlus: 90 (90) | ClosurePlus: 12/81 = 14.81% |
Surgery: 90 (90) | Surgery: 9/81 = 11.11% | |||
Odds ratio: 1.39 | ||||
UGFS vs. Surgery | ||||
Shadid [66] | 2012 | 24 (UGFS: 213 Surgery: 177) | UGFS: 230 (230) | UGFS: 24/213 = 11.27% |
Surgery: 200 (200) | Surgery: 16/177 = 9.04% | |||
Odds ratio: 1.28 | ||||
Foam Sclerotherapy vs Surgery | ||||
Belcaro [63] | 2000 | 120 | Foam Sclerotherapy: 148 | Foam Sclerotherapy: 56/148 = 37.84% |
Surgery: 155 | Surgery: 38/155 = 24,52% | |||
Surgery: 200 (200) | Odds Ratio: 1.87 | |||